

Catalog	Unit
TBI4660-5MG	5 mg
TBI4660-25MG	25 mg

### Product Details

**Formal Name:** 2-Methyl-1-[[4-[6(trifluoromethyl)-2-pyridinyl]-6-[[2-(trifluoromethyl)-4-pyridinyl]amino]-1,3,5-triazin-2-yl]amino]-2-propanol

**Alternate Names:** AG-221

**Molecular Formula:** C<sub>19</sub>H<sub>17</sub>F<sub>6</sub>N<sub>7</sub>O

**Formula Weight:** 473.38

**CAS Number:** 1446502-11-9


**Purity:** >98%

**Formulation:** powder

**Solubility:** Soluble in DMSO (up to 25 mg/ml)

**Storage:** -20°C

**Stability:** ≥ 1 year.



### Applications

Mutant isocitrate dehydrogenase 2 (IDH2) inhibitor

### Functions

Enasidenib is a potent (IC<sub>50</sub>'s = 100 nM IDH2R140Q homodimer, 30 nM IDH2R140Q/WT heterodimer and 10 nM IDH2R172K/WT heterodimer) and selective inhibitor of mutant isocitrate dehydrogenase 2 (IDH2). It suppressed the production of the oncometabolite (R)-2-Hydroxyglutarate (a competitive inhibitor of αKG-dependent dioxygenases which leads to epigenetic dysregulation) and induced cellular differentiation in primary human IDH2 mutation-positive acute myeloid leukemia cells. Recently approved for clinical use by the FDA.

### Application Procedures

First dissolved in DMSO (up to 25 mg/ml), then diluted to aqueous buffer. Solutions in DMSO may be stored at -20°C for up to 3 months.

**For research use only.**